AnaptysBio Receivables Turnover from 2010 to 2024

ANAB Stock  USD 22.40  1.09  5.11%   
AnaptysBio's Receivables Turnover is increasing over the years with stable fluctuation. Receivables Turnover is expected to dwindle to 2.38. From 2010 to 2024 AnaptysBio Receivables Turnover quarterly data regression line had arithmetic mean of  22.36 and r-squared of  0.07. View All Fundamentals
 
Receivables Turnover  
First Reported
2010-12-31
Previous Quarter
2.50430594
Current Value
2.38
Quarterly Volatility
26.51470397
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AnaptysBio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AnaptysBio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 19 M or Selling General Administrative of 44 M, as well as many indicators such as Price To Sales Ratio of 31.93, Dividend Yield of 0.0 or PTB Ratio of 6.22. AnaptysBio financial statements analysis is a perfect complement when working with AnaptysBio Valuation or Volatility modules.
  
Check out the analysis of AnaptysBio Correlation against competitors.
For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.

Latest AnaptysBio's Receivables Turnover Growth Pattern

Below is the plot of the Receivables Turnover of AnaptysBio over the last few years. It is AnaptysBio's Receivables Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AnaptysBio's overall financial position and show how it may be relating to other accounts over time.
Receivables Turnover10 Years Trend
Pretty Stable
   Receivables Turnover   
       Timeline  

AnaptysBio Receivables Turnover Regression Statistics

Arithmetic Mean22.36
Geometric Mean12.21
Coefficient Of Variation118.60
Mean Deviation20.75
Median10.89
Standard Deviation26.51
Sample Variance703.03
Range69.7376
R-Value0.27
Mean Square Error703.48
R-Squared0.07
Significance0.34
Slope1.58
Total Sum of Squares9,842

AnaptysBio Receivables Turnover History

2024 2.38
2023 2.5
2022 7.25
2019 72.12
2018 28.74
2017 6.25
2016 3.12

About AnaptysBio Financial Statements

AnaptysBio stakeholders use historical fundamental indicators, such as AnaptysBio's Receivables Turnover, to determine how well the company is positioned to perform in the future. Although AnaptysBio investors may analyze each financial statement separately, they are all interrelated. For example, changes in AnaptysBio's assets and liabilities are reflected in the revenues and expenses on AnaptysBio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in AnaptysBio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Receivables Turnover 2.50  2.38 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:
Check out the analysis of AnaptysBio Correlation against competitors.
For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.05)
Revenue Per Share
2.086
Quarterly Revenue Growth
8.047
Return On Assets
(0.18)
Return On Equity
(1.62)
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.